| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 03.06.06 | Tiny Terror Kicks Tail: San Francisco's Top Chihuahua Advances to America's Fastest Chihuahua Championship Race in San Diego | 250 | PR Newswire | SAN FRANCISCO, June 3 /PRNewswire/ -- They might be America's smallest breed of dog, but they sure are lightning-quick. Chihuahuas of all sizes came together today to compete for the coveted title... ► Artikel lesen | |
| 03.06.06 | Pharmacyclics Additional Data and New Analyses From Pivotal Phase 3 SMART Trial Presented at ASCO 2006 | 33 | PR Newswire | SUNNYVALE, Calif., June 3 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced that additional new data and analyses supporting the company's decision to file a New Drug Application (NDA)... ► Artikel lesen | |
| 03.06.06 | Lilly Breast Cancer Studies Explore Potential Role of Pharmacogenomics in Customizing Chemotherapy | 43 | PR Newswire | ATLANTA, June 3 /PRNewswire-FirstCall/ -- At the 42nd American Society of Clinical Oncology (ASCO) annual meeting in Atlanta, Ga., Eli Lilly and Company, a leader in thoracic cancer, unveiled two breast... ► Artikel lesen | |
| 03.06.06 | Tiny Terror Kicks Tail: Chicago's Top Chihuahua Repeats Last Year's Winning Performance; Advances to America's Fastest Chihuahua Championship Race in San Diego | 83 | PR Newswire | CHICAGO, June 3 /PRNewswire/ -- They might be America's smallest breed of dog, but they sure are lightning-quick. Chihuahuas of all sizes came together today to compete for the coveted title of America's... ► Artikel lesen | |
| 03.06.06 | Data From a Randomized Phase II Study of Dasatinib or 800 Mg/Day Imatinib- Mesylate (Gleevec(R)) Presented at the 42nd Annual Meeting of the American Society of Clinical Oncology | 354 | PR Newswire | ATLANTA, June 3 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company today presented interim data from a randomized Phase II study of the investigational compound dasatinib (140 mg/day) or imatinib... ► Artikel lesen | |
| 03.06.06 | Gleevec(R) Sets New Treatment Standard in Chronic Myeloid Leukemia With High Overall Survival, Increasing Response and Decreasing Progression | 324 | PR Newswire | EAST HANOVER, N.J., June 3 /PRNewswire/ -- Response rates to Gleevec(R) (imatinib mesylate)* tablets continue to increase substantially over time while the yearly risk of progression to advanced disease... ► Artikel lesen | |
| 03.06.06 | Tiny Terror Kicks Tail: Miami's Top Chihuahua Advances to America's Fastest Chihuahua Championship Race in San Diego | 36 | PR Newswire | MIAMI, June 3 /PRNewswire/ -- They might be America's smallest breed of dog, but they sure are lightning-quick. Chihuahuas of all sizes came together today to compete for the coveted title of America's... ► Artikel lesen | |
| 03.06.06 | Tiny Terror Kicks Tail: Dallas' Top Chihuahua Advances to America's Fastest Chihuahua Championship Race in San Diego | 34 | PR Newswire | DALLAS, June 3 /PRNewswire/ -- They might be America's smallest breed of dog, but they sure are lightning-quick. Chihuahuas of all sizes came together today to compete for the coveted title of America's... ► Artikel lesen | |
| 03.06.06 | Cell Genesys Reports Long-Term Follow-Up Data From Phase 2 Trial of GVAX(R) Immunotherapy For Leukemia in Chronic Myelogenous Leukemia | 42 | PR Newswire | SOUTH SAN FRANCISCO, Calif., June 3 /PRNewswire-FirstCall/ -- Cell Genesys, Inc. today reported encouraging long-term follow-up data from a Phase 2 trial of GVAX(R) immunotherapy for chronic myelogenous... ► Artikel lesen | |
| 03.06.06 | Genzyme and Berlex Oncology Announce Interim Results of Campath in First-Line Study of Chronic Lymphocytic Leukemia at ASCO | 33 | PR Newswire | CAMBRIDGE, Mass. and WAYNE, N.J., June 3 /PRNewswire-FirstCall/ -- Genzyme Corporation and Berlex Oncology, a business unit of Berlex Laboratories, a U.S. affiliate of Schering AG, Germany (FSE: SCH... ► Artikel lesen | |
| 03.06.06 | Study Explores Use of PROCRIT(R) (Epoetin Alfa) Once Every Two Weeks As Initiation Treatment for Chemotherapy-Related Anemia | 44 | PR Newswire | ATLANTA, June 3 /PRNewswire/ -- New study results presented today suggest that 80,000 units of PROCRIT(R) (Epoetin alfa) administered once every two weeks demonstrated comparable changes in hemoglobin... ► Artikel lesen | |
| 03.06.06 | New Data Show Impressive Survival Benefit for Herceptin in Early-Stage HER2-Positive Breast Cancer | 19 | PR Newswire | BASEL, Switzerland, June 3 /PRNewswire/ --
- Follow-up From the International HERA Trial Continues to Demonstrate
Significant Patient Benefits From Herceptin
New 23-month follow-up data... ► Artikel lesen | |
| 03.06.06 | Serum HER-2/neu Change Predicts Clinical Outcome to Trastuzumab-Based Therapy | 22 | PR Newswire | ATLANTA, June 3 /PRNewswire/ -- Bayer HealthCare, a member of the Bayer Group , today announced findings from a study using Bayer Diagnostics' Serum HER-2/neu Test that demonstrated metastatic breast... ► Artikel lesen | |
| 03.06.06 | Keryx Biopharmaceuticals, Inc. Announces Positive Data of KRX-0401 (Perifosine) in Patients With Advanced Renal Cell Carcinoma | 13 | PR Newswire | NEW YORK, June 3 /PRNewswire-FirstCall/ -- Keryx Biopharmaceuticals, Inc. today announced positive data of KRX-0401 (perifosine) in patients with advanced renal cell carcinoma (RCC). These patients... ► Artikel lesen | |
| 03.06.06 | Eradication of Minimal Residual Disease Reported in Patients with Chronic Lymphocytic Leukemia Treated with Chemotherapy Plus Genasense(R) | 27 | PR Newswire | BERKELEY HEIGHTS, N.J., June 3 /PRNewswire-FirstCall/ -- Genta Incorporated announced the presentation of data showing that its lead anticancer drug, Genasense(R) (oblimersen sodium) Injection, induced... ► Artikel lesen | |
| 03.06.06 | Results of a Meta-Analysis Show Benefits of Taxotere(R) (Docetaxel) Regimens in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) | 27 | PR Newswire | PARIS, June 3 /PRNewswire-FirstCall/ -- Sanofi-aventis announced today that a meta-analysis performed on seven clinical trials in patients with advanced non-small cell lung cancer showed that patients... ► Artikel lesen | |
| 03.06.06 | Encouraging Phase I Trial Results for XL647 in Patients with Advanced Solid Malignancies Presented at ASCO | 26 | PR Newswire | ATLANTA, June 3 /PRNewswire-FirstCall/ -- Exelixis, Inc. announces that updated results from a Phase I trial of XL647 in patients with advanced solid malignancies were reported today. XL647 is an... ► Artikel lesen | |
| 03.06.06 | New Data Show That Five Years of Treatment With Arimidex(R) (anastrozole) Did Not Cause Osteoporosis in Early Breast Cancer Patients With Normal Bone Mineral Density at Outset | 38 | PR Newswire | ATLANTA, June 3 /PRNewswire-FirstCall/ -- New data reported today from a five-year update from the bone sub protocol of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial (Abstract # 511)... ► Artikel lesen | |
| 03.06.06 | Largest Ever Data Set Shows Consistent Benefits With Avastin When Used in Combination With Different Chemotherapy Treatments | 15 | PR Newswire | BASEL, Switzerland, June 3 /PRNewswire/ --
- Real World Practice Confirms Avastin's Efficacy and Safety in Advanced
Colorectal Cancer
New data from 4,000 patients show that Avastin... ► Artikel lesen | |
| 03.06.06 | Exelixis' XL880, the First Orally-Available MET Inhibitor in Clinical Development, Continues to Show Promise in a Phase I Trial in Patients With Advanced Solid Tumors | 19 | PR Newswire | ATLANTA, June 3 /PRNewswire-FirstCall/ -- Exelixis, Inc. announces that updated results from a Phase I trial of XL880 in patients with advanced solid malignancies were reported today. XL880 is an... ► Artikel lesen |
Seite:
1 2 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| TUI | 3.666 |
| NVIDIA | 3.553 |
| TESLA | 2.961 |
| SUPER MICRO COMPUTER | 2.853 |
| BAYER | 2.763 |
| VARTA | 2.448 |
| NEL | 2.403 |
| RHEINMETALL | 2.316 |
| DEUTSCHE BANK | 1.731 |
| RENK GROUP | 1.724 |
| SAP | 1.526 |
| AIXTRON SE | 1.497 |
| DEUTSCHE LUFTHANSA | 1.444 |
| BASF | 1.346 |
| EVOTEC | 1.326 |
| BYD | 1.313 |
| ALLIANZ | 1.129 |
| PLUG POWER | 1.082 |
| RWE | 1.072 |
| COMMERZBANK | 1.045 |
| INFINEON | 1.043 |
| MERCEDES-BENZ | 943 |
| VOLKSWAGEN | 897 |
| THYSSENKRUPP | 888 |
| NORDEX | 849 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
